Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.46 |
| ▸ | HTR2A | P28223 | 10/20 | 0.46 |
| ▸ | HTR2B | P41595 | 9/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630335 | 1.00 | HTR2C (0.46) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL12279878 | 0.85 | HTR2C (0.47) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL9288127 | 0.82 | HTR2C (0.69) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL12280030 | 0.80 | CHRNB2 (0.43) | HTR2CCHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL31597697 | 0.80 | HTR2C (0.58) | HTR2CHTR2AHTR2BCA1CA2 | |
| SCHEMBL12279234 | 0.80 | HTR2C (0.58) | HTR2CHTR2AHTR2BCA1CA2 | |
| Hydrochloric Acid SCHEMBL23538187 | 0.79 | HTR2C (0.57) | HTR2CHTR2AHTR2BCA1CA2 | |
| Hydrochloric Acid SCHEMBL29950615 | 0.79 | HTR2C (0.57) | HTR2CHTR2AHTR2BCA1CA2 | |
| SCHEMBL6491638 | 0.77 | HTR2C (0.72) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL14549122 | 0.76 | HTR2C (0.42) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | HTR2C 743/4885HTR2A 928/4885HTR2B 1114/4885 |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | HTR2C 743/4885HTR2A 928/4885HTR2B 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.